Description: LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. Its lead product candidate is LB-001 that is been developed for the treatment of Methylmalonic Acidemia, a life-threatening disease that presents at birth. LogicBio Therapeutics, Inc. was founded in 2014 and is based in Cambridge, Massachusetts.
Home Page: www.logicbio.com
LOGC Technical Analysis
65 Hayden Avenue
Lexington,
MA
02421
United States
Phone:
617 245 0399
Officers
| Name | Title |
|---|---|
| Mr. Frederic Chereau M.B.A. | Pres, CEO & Director |
| Dr. Mark A. Kay M.D., Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director |
| Dr. Daniel J. Gruskin M.D. | Chief Medical Officer |
| Dr. Leszek Lisowski M.B.A., Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Adi Barzel Ph.D. | Co-Founder |
| Mr. Joshua Blacher | Interim CFO, Principal Financial Officer & Principal Accounting Officer |
| Dr. Matthias Hebben Ph.D. | Global VP & Head of Technology Devel. |
| Dr. Mariana Nacht Ph.D. | Chief Scientific Officer |
| Ms. Andrea Paul J.D. | Gen. Counsel & Corp. Sec. |
| Ms. Grace Lochhead | VP & Head of HR |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2937 |
| Price-to-Sales TTM: | 6.3419 |
| IPO Date: | 2018-10-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 62 |